Study of rentosertib for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older.
- You have a firm diagnosis of idiopathic pulmonary fibrosis (IPF) based on a chest CT scan done within the last 3 months.
- Your lung function tests show a forced vital capacity (FVC) of at least 45% of normal and a DLCO (measure of oxygen exchange) between 25% and less than 80% of normal.
- You are either on a stable dose of nintedanib or pirfenidone for at least 12 weeks, or you have not taken these medications for at least 8 weeks and do not plan to start.
- You do not have other serious lung conditions like asthma or active infections, and your heart is generally stable.
- You are not pregnant, breastfeeding, or planning pregnancy, and you agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial studies ifetroban, an oral medicine, in people with idiopathic pulmonary fibrosis (IPF) to see if it improves outcomes and is safe. It may be an option if your IPF is confirmed on lung scans and your lung function tests meet the trial thresholds.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.